Compass Therapeutics Inc. (OTCMKTS:CMPX) Stocks Continues to Consolidate: Now What?

Compass Therapeutics Inc. (OTCMKTS:CMPX) stock continued to move within a narrow over the past few weeks.

Market Action

In the previous trading session, CMPX stock went down 2.60% to $3.41. A total of 332 shares traded for the session hands, above its average volume of 2.90K shares. The stock opened at $3.51 and moved in a range of $3.4100 – 3.5100.

Key Trigger

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Compass Therapeutics announced today that the Phase 1 monotherapy dose escalation and expansion study data for CTX-009 (ABL001/ES104), a bispecific dual angiogenesis inhibitor targeting DLL4 and VEGF-A, has been selected for an oral plenary presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held virtually on October 7-10, 2021. The oral presentation will include single agent safety, tolerability, exploratory DLL4 expression analysis, and clinical activity data for CTX-009 in heavily pre-treated patients with metastatic, anti-VEGF-resistant solid tumors, mainly of colorectal and gastric origin.

Title: Phase Ia/Ib Dose-Escalation Study of ABL001 (CTX-009, Bispecific Antibody Targeting DLL4 and VEGF-A) as a Single Agent in Patients with Advanced Solid Tumors

Abstract Number: 4749

Session Title: Plenary Session 2: New Drugs on the Horizon I

Presenter: Jeeyun Lee, MD, Samsung Medical Center, Seoul, Korea

Date: October 8, 2021 at 10:45 a.m. EDT